MREO241115C5000
- 0.20
- +0.05+33.33%
Mereo BioPharma Newsroom
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
Baird Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $8
Mereo BioPharma Group Plc (MREO): A Bull Case Theory
Mereo BioPharma Group Down Over 9%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Mereo BioPharma CFO Sells Over $121k in Company Stock
Express News | Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
New Additions to Roth MKM's ADR Portfolio for September
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
Express News | Watching Shares Of Mereo BioPharma Group; Positive Mentions From A Popular Newsletter
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
Liquidia, Shake Shack And Other Big Stocks Moving Lower In Monday's Pre-Market Session
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
Buy Rating Affirmed for Mereo Biopharma on Strong Financials and Promising Pipeline Progress
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Mereo Biopharma on Strong Clinical and Financial Prospects
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7